Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Wednesday

Fortress Biotech (NASDAQ:FBIO - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $11.62 million for the quarter.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last issued its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.53. The company had revenue of $15.12 million during the quarter, compared to analyst estimates of $16.30 million. On average, analysts expect Fortress Biotech to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fortress Biotech Stock Performance

Shares of Fortress Biotech stock opened at $1.74 on Wednesday. The firm has a market cap of $51.45 million, a PE ratio of -0.57 and a beta of 1.85. The firm's 50-day simple moving average is $1.63 and its 200-day simple moving average is $1.76. Fortress Biotech has a 1 year low of $1.33 and a 1 year high of $2.89.

Analyst Ratings Changes

Separately, Roth Mkm reaffirmed a "buy" rating and set a $16.00 target price (up previously from $15.00) on shares of Fortress Biotech in a report on Tuesday, March 11th.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.